← All stocks

Braveheart Bio, Inc.

BRVE Net buying

CIK 0002131524 #2086 in the set updated 17 Sep 2026

Bought (120 mo)

$159.03M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

+$159.03M

+$159.03M against sales at will

By person

11 insiders · 13 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Forbion Growth Opportunities Fund III Cooperatief U.A. entity

10% owner

$64.80M (2)

—

+$64.80M

21,826,024

$392.87M

+1,879%

Chimovits Erez

Director

$34.92M (2)

—

+$34.92M

273,333

$4.92M

—

ORBIMED ADVISORS LLC entity

Director

$34.92M (2)

—

+$34.92M

273,333

$4.92M

—

AH Bio Fund IV, L.P. entity

10% owner

$19.80M (1)

—

+$19.80M

10,232,420

$184.18M

—

Murdoch Travis

CEO and President

$1.50M (1)

—

+$1.50M

2,940,670

$52.93M

+2.9%

Viehbacher Christopher

Director

$1.50M (1)

—

+$1.50M

609,519

$10.97M

+15.8%

Lubner David Charles

Director

$999.99K (1)

—

+$999.99K

55,555

$999.99K

—

Rickey James Paul

Chief Financial Officer

$499.99K (1)

—

+$499.99K

520,927

$9.38M

+5.6%

Malek David I

Director

$74.99K (1)

—

+$74.99K

533,845

$9.61M

+0.8%

Anderson Michele A.

Chief Development Officer

$20.00K (1)

—

+$20.00K

332,161

$5.98M

+0.3%

Jiangsu Hengrui Pharmaceuticals Co., Ltd. entity

10% owner

—

7,420,091

$133.56M

—

No percentages here. Braveheart Bio, Inc. reports its share count only per share class, which the XBRL frames API does not carry.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 14

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 3

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 51,940,638

History held since 7 Aug 2026